You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Alchemia Limited (ACL) is a biotechnology company which develops new human therapeutics based on its proprietary drug discovery and expands drug targeting and synthesis technologies in Australia and USA. ACL’s pipeline of assets is built on two platform technologies: HyACT (targeted cancer delivery) and VAST (drug discovery). FDA’s approved drug is Fondaparinux that is already in market.
Strategy Analysis: ACL will use its technologies to develop a sustainable pipeline of patented products with which to target large and growing pharmaceutical markets.
Alchemia reported net loss of $5.9m for the half-year ended 31 December 2012. Revenue from ordinary activities were $9.44m. Basic and Diluted EPS were (2.1) cents compared to (2.9) cents last year. The net operating cash outflow was $7.71m compared to an outflow of $4.67m in the pcp. No dividend was declared.
Handing over, what if you need someone else to make decisions for you? There are times in your life when you can't fulfil your financial obligations personally.
The Age 25/05/2013 |
In the mid-1960s, when Australia's trade minister Sir John McEwen was urging Holden and Ford to seek export markets in Asia, the leader of one of Asia's poorest countries decided his country needed a car industry.
The Age 25/05/2013 |
Debts to tradespeople and suppliers by collapsed builder National Buildplan Group have blown out to $58 million but administrators say they are likely to recoup only cents in the dollar.
The Age 25/05/2013 |
There's a simple message in what appeared to be conflicting statements from the Federal Reserve, its chairman, Ben Bernanke, and an assortment of other Fed heavies this week about the timing of a move to re-tighten monetary policy.
The Age 25/05/2013 |
Investors are contemplating a future without support from one of the biggest drivers of the global economy in recent years - the US Federal Reserve.
Already a member? 
$ 0.360
